An early clinical trial at U-M finds that a Wee1 inhibitor, combined with radiation and gemcitabine, is safe and potentially effective in pancreatic cancer treatment.
Researchers have shown how tumor-associated macrophages release compounds that block gemcitabine in the most common type of pancreatic cancer
More funding, scientific insights and clinical advances have started to drive progress in this challenging disease, and researchers see potential for immunotherapy to revolutionize its future.
New research finds the protein PDX1 is critical for cancer growth, but blocking it may lead to more aggressive tumors.
A new national initiative will change the face of clinical trials for pancreatic cancer through collaboration among researchers, clinicians and pharma.
A metabolic cross-talk pathway between cancer and noncancer cells in pancreatic tumors delivers an alternative nutrient to the cancer cells, facilitating tumor growth.